HTL Biotechnology inaugurates a new production line dedicated to sterile Hyaluronic Acid
As part of National Biomanufacturing Day 2025, HTL Biotechnology inaugurates a new production line dedicated to Hyaluronic Acid.
Hear from experts on why the quality and origin of raw materials are important for the efficacy and safety of treatments in aesthetic medicine:
In this first interview, Dr. Abs Settipalli, an aesthetic medicine and biotechnology expert, talks about various topics concerning raw materials in aesthetic medicine such as:
Next we have Dr. Tingsong Lim, a renowned aesthetic doctor from Malaysia, who talks about:
Finally, Dr. Nabila Azib, a leading aesthetic physician from Morocco, shares her valuable insights on:
With strong expertise in the field, HTL Biotechnology is a leader in the development and manufacturing of premium quality biopolymers for medical aesthetics
Click on the link or contact our team to learn more about our biopolymers.
HTL Biotechnology’s industrial platform is the backbone of its leadership in pharmaceutical-grade biopolymers. Built on more than 30 years of expertise, it combines not only reliability, and the highest quality standards, but also sustainability.
In the realm of modern medicine, few biopolymers have demonstrated as much clinical versatility as hyaluronic acid (HA).
Hyaluronic Acid (HA) has already secured its place as a gold-standard biopolymer across medical and aesthetic fields. Celebrated for its unique viscoelasticity, hydration capacity, and biocompatibility, HA has long been used in ophthalmic surgery, joint viscosupplementation, wound healing, and dermal fillers. But today, HA is undergoing a radical transformation. It’s becoming an active, programmable platform—a cornerstone of the next generation of drug delivery and regenerative medicine.